ImmunoGen (IMGN) option implied volatility, says to present data from FORWARD II trial at ASCO
Get Alerts IMGN Hot Sheet
Join SI Premium – FREE
Immunogen (NASDAQ: IMGN) May call option implied volatility is at 120, June is at 77; compared to its 52-week range of 62 to 156 into announcing positive data from the FORWARD II trial evaluating mirvetuximab soravtansine in multiple combination cohorts in patients with folate receptor alpha (FRalpha)-positive ovarian cancer. Results from the cohort assessing mirvetuximab in combination with Avastin in patients with platinum-resistant disease will be presented at the 2018 American Society of Clinical Oncology, or ASCO, Annual Meeting.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Skechers USA (SKX) August 55 puts active
- BHP Group (BHP) 30-day option implied volatility near low end of range
- Microsoft (MSFT) April weekly option implied volatility into quarter results
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!